BioSpace News Archive

Wilburn Medical USA is proud to announce that they have distributed their one millionth CareStart COVID-19 rapid test.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET to discuss second quarter 2021 financial results and provide a general business update.

Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has granted orphan designation for bomedemstat, a lysine-specific demethylase-1 (LSD1) inhibitor, for the treatment of essential thrombocythemia (ET).

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), presented findings from a new observational safety study conducted in the U.S. that found no unexpected adverse pregnancy outcomes in pregnant people who were vaccinated with the company’s cell-based quadrivalent seasonal influenza vaccine (QIVc) during pregnancy.

Ocugen, Inc. (NASDAQ: OCGN), today announced that it will host a conference call to discuss its second quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, August 6, 2021.

ALK and the pharmaceutical company China Grand Pharmaceutical and Healthcare Holdings Limited (”Grandpharma”) today announced an exclusive licensing agreement that will see ALK’s AAI Jext® registered and launched in China, and will expand ALK’s presence in the country.

Global Cancer Technology today announced that the company has licensed biomarker technology from Baylor Scott & White Research Institute (BSWRI) under an exclusive option to support GCT’s research efforts towards a treatment for glioblastoma.

The report offers assessment and analysis of the Spatial Omics market on a global and regional level.